Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an increasingly recognized cause of ventricular tachycardia and sudden cardiac death in young people, notably young athletes. The best treatment is not clear, although options include antiarrhythmic drugs, radiofrequency ablation, and implantable defibrillators.
RRHYTHMOGENIC right ventricular cardiomyopathy (ARVC) has recently been recognized as a cause of ventricular tachycardia and sudden death in young people.
Because the sudden death of a young, seemingly healthy adult is such a devastating event, much attention has been focused on the causes of sudden death in athletes, with the goal of implementing preparticipation screening programs. Although left heart cardiomyopathies such as hypertrophic cardiomyopathy, coronary anomalies, and valvular heart disease account for most of such cases in the United States (TABLE 1), 1,2 ARVC is now believed to be an important cause as well.
This review highlights the major features of this enigmatic disease with specific attention to the symptoms that should lead a physician to suspect it, and the diagnostic tests used to define it.
■ THREE MAIN FEATURES
According to the World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies, 3 ARVC, also known as arrhythmogenic right ventricular dysplasia, is distinct from the more familiar forms of cardiomyopathy (dilated, hypertrophic, and restrictive) and is characterized by three features:
• Progressive fibrofatty replacement of right ventricular myocardium • Strong familial transmission • Presentation with symptomatic arrhythmias or sudden death.
■ PREVALENCE DIFFICULT TO ESTIMATE
The prevalence of ARVC is difficult to estimate, since many cases are only recognized postmortem. Earlier in the disease, cases are unrecognized because we lack effective screening tests and commonly accepted diagnostic criteria. Nonetheless, the disease is uncommon. Most reports of ARVC are from Europe (particularly the Veneto region of Italy) and the United States. These seemingly endemic regions may simply be areas where the disease is best understood and most often investigated.
Patients with ARVC are predominantly male, with a male-to-female ratio of 2.7 to 1 and a mean age at onset of symptoms ranging from the late 20s to early 30s. The disease almost always occurs after puberty, though it has been detected in persons of all ages. 3 ■ PATHOPHYSIOLOGY:
A TWO-STEP PROCESS ARVC is familial in more than 50% of patients, with the more common form being autosomal dominant. Rare recessive forms have also been characterized, particularly in a region of Greece. 4 The disease is thought to progress in a two-step process involving first a genetic predisposition to fatty infiltration of the right ventricle and later transformation from a pure fatty infiltration to a fibrofatty form involving apoptosis or myocarditis, possibly as a result of some unknown environmental stimulus or virus. 5 ARVC was initially thought to involve the right ventricle only, but it is now known that most cases involve both ventricles. 6, 7 The disease progresses as right and left ventricular function deteriorate over time. In its end stage, ARVC is clinically indistinguishable from dilated cardiomyopathy, and many patients thought to have idiopathic dilated cardiomyopathy are discovered at autopsy to have had ARVC. 6 
■ CLINICAL MANIFESTATIONS
Asymptomatic ARVC is uncommonly recognized unless a physician is alerted to a family history of the disease. Furthermore, most athletic screening programs cannot detect the disease by a routine history and physical examination. ARVC may be suspected on the basis of electrocardiographic (ECG) findings, though this requires that the clinician be alert to often subtle or sometimes nonspecific patterns.
Therefore, patients with ARVC generally present as young adults with symptoms on initial presentation that include presyncope, syncope, palpitations, premature ventricular contractions (PVCs), ventricular arrhythmias, right or left heart failure, and sudden cardiac 
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arrest. Often, sudden cardiac arrest is the first manifestation of ARVC among persons participating in sports or strenuous activity. This is best documented in Italy, where ARVC accounts for 20% of all sudden cardiac deaths in people younger than 35 years. 8, 9 The McKenna criteria are the most widely accepted criteria for the diagnosis of ARVC. 10 The Arrhythmogenic Right Ventricular If clinical suspicion is high and initial diagnostic tests are equivocal, then one should proceed with MRI or electon-beam ("ultrafast") CT. The overall accuracy of ECG findings for diagnosing ARVC has not been established. Many young adults have T-wave changes in the precordial leads ("juvenile T waves"), and conduction abnormalities are nonspecific. Only the infrequently encountered epsilon waves are highly suggestive of the disorder.
For patients with ECG findings that suggest ARVC, a signal-averaged ECG can be performed. This test has a reported sensitivity of 57%, a specificity of 95%, and a positive predictive value of 92% for the detection of abnormal late potentials that are the substrate for ventricular tachycardia. The more extensive the disease, the greater the likelihood that the signal-averaged ECG will detect it. 13 Echocardiography An echocardiogram is an integral part of the diagnostic evaluation of patients with syncope, arrhythmias, and cardiac arrest. Structural heart disease may be diagnosed echocardiographically in most patients with these presenting symptoms. The value of echocardiography for patients with palpitations and no documented arrhythmias is less certain.
Echocardiographic evaluation of a patient with suspected ARVC should focus on assessing regional or global enlargement or dysfunction of the right ventricle. The three most frequent sites of dysplasia (the "triangle of dysplasia") are the outflow tract, the apex, and the inflow portion of the right ventricle (FIG-URE 3) . 12 Specific findings in these areas include diastolic outpouchings and systolic aneurysms (FIGURE 4) .
In a patient with suspected ARVC, echocardiographic evidence of diffuse right ventricular enlargement strongly supports the diagnosis. 14 However, other causes of right ventricular disorders such as congenital, myocardial, or valvular diseases or shunts should be sought before the diagnosis of ARVC is made. 15 Echocardiography is often the first test that demonstrates the characteristic abnormalities of ARVC, though its accuracy is variably reported and it is best used in patients with a high likelihood of disease. 16 A normal echocardiogram does not exclude the diagnosis of ARVC, since early forms of the disease may not be apparent.
Radionuclide cardiac studies
Radionuclide cardiac studies have been validated as a noninvasive alternative to right ventriculography and echocardiography. 17 In some patients, the right ventricle's anterior location and irregular shape make it difficult to evaluate by echocardiography. In these patients, radionuclide scans are useful in measuring right ventricular size and function. Some investigators used radionuclide studies to assess right ventricular wall motion during exercise, with right ventricular dysfunction during stress suggesting the diagnosis of ARVC.
Magnetic resonance imaging and electron-beam computed tomography
Though expensive, time-consuming, and limited to specialized centers, MRI is considered by many to be the definitive noninvasive test for ARVC. In patients with suspected ARVC, MRI can detect fatty infiltration or thinning of the infundibulum and the diaphragmatic free wall of the right ventricle. The pathognomonic distribution of fatty infiltration is in the RV free wall, where MRI shows a high signal intensity diffusely present (FIGURE 5). 18 The location of a high-intensity fat signal must be contrasted with the normal distribution of fat in the human heart, most notably in the atrio-ventricular groove. MRI can also be used to correlate the morphologic findings of wall thinning or outpouchings with dyskinetic RV segments on gradientecho pulse sequences. 19 Some centers prefer electron-beam computed tomography as an alternative to MRI. Like MRI, electron-beam computed tomography detects ARVC by the presence of epicardial adipose tissue, low-attenuation trabeculations, scalloping of the right ventricular free wall, and intramyocardial fat deposits. It can also be used to find fatty replacement of left ventricular myocardium. 20, 21 Right ventricular angiography Before echocardiography was commonly used, right ventriculography was frequently used as a reliable test for localized abnormalities such as sacculations, dilation, and dysfunction of the right ventricle. Since then, however, echocardiography has proved to be equivalent in terms of image quality and is less invasive, cheaper, more readily available, and simpler to perform. 22 
Endomyocardial biopsy
The gold standard for diagnosing ARVC is a transmural biopsy specimen obtained at autopsy or during heart transplantation.
Endomyocardial biopsies are less sensitive but can be obtained in living, nontransplant patients with suspected ARVC. However, a paradox exists in that the process of fibrofatty replacement of the myocardium occurs preferentially in the right ventricular free wall, but endomyocardial biopsies are traditionally obtained from the right ventricular portion of the interventricular septum. Biopsy of the right ventricular free wall is considered risky with the potential for perforation and tam-
ARVC MCRAE AND COLLEAGUES
The 'triangle of dysplasia' in ARVC 23 If the biopsy of the right ventricular septum reveals fibrofatty replacement of the right ventricle, then the diagnosis of ARVC is secured. If the biopsy is normal, however, the specimen could be falsely negative.
Under proposed criteria for histomorphometric evaluation of biopsy specimens, the diagnosis of ARVC requires that there be fewer than 45% residual myocytes, more than 40% fibrous tissue, and more than 3% fatty tissue. These criteria have a sensitivity of 67% and a specificity of 92%. 24 
Brain natriuretic peptide
Future tests for ARVC may include direct genetic probes. Until then, measurement of proteins released in response to ARVC offers useful diagnostic and prognostic information. Plasma levels of brain natriuretic peptide were used in a small study to distinguish between ARVC and another form of idiopathic right ventricular outflow-tract tachycardia. 25 In addition, plasma levels of the peptide were found to be inversely related to the right ventricular ejection fraction, providing a potential method by which progression of the disease could be monitored.
■ TREATMENT IS CONTROVERSIAL
The optimal treatment of ARVC is controversial. Options are many and include antiarrhythmic drugs with serial electrophysiology studies, radiofrequency ablation, implantable cardioverter-defibrillator (ICD) placement, surgical disarticulation, and heart transplantation. Once the diagnosis of ARVC is made, the patient should refrain from participating in competitive sports or other intense exertional activities.
Drug therapy. The largest study (81 patients) 26 of drug therapy in ARVC found sotalol to be the most effective medication, with a success rate of 68% as determined by the inability to reproduce sustained ventricular tachycardia during serial electrophysiology studies. Amiodarone was successful in only 15% of cases, and class I agents were universally unsuccessful. The investigators concluded that if sotalol therapy failed, more invasive treatments should be considered.
Radiofrequency catheter ablation is effective for some patients with ventricular tachycardia refractory to antiarrhythmic therapy. [27] [28] [29] Implantable cardioverter-defibrillators. Since the disease may be progressive, ablation may not be curative and many specialists recommend an ICD once the diagnosis is made. A patient who has been resuscitated from cardiac arrest can be treated with antitachycardia pacing or defibrillation. ICD therapy does not obviate the need for adjunct drug treatment to decrease the number of shocks delivered. Initially there were concerns about placing transvenous leads into the endocardium of the diseased right ventricle of a patient with ARVC and uncertainty about the ability of the device to correctly sense and deliver shocks. Small studies, however, have since confirmed that transvenous endocardial lead placement is safe and that effective therapy can be delivered. 29 Surgical therapy, though no longer contemporary practice, involves disarticulation of the right ventricle, which separates it from the left ventricle and prevents it from propagating the arrhythmia to the left ventricle.
Cardiac transplantation is ultimately an option if the patient has progressive biventricular failure with increasing amounts of ventricular tachycardia. 
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